The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2017 | Do immunoglobulin receptor interactions play a role in CLL?
Paolo Ghia, MD, PhD from the San Raffaele Hospital, Milan, Italy, provides us an overview of a prospective clinical study in which patients with chronic lymphocytic leukemia (CLL) are screened according to the affinity of their immunoglobulin receptors and then treated, with a long-term follow-up of 2-3 years. He expects that those with weak receptor interactions with respond well to therapy whereas those with strong interactions will not. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
